在接受化疗免疫治疗的高级非小细胞肺癌患者中,免疫疗法相关的不良事件:斯宾纳克研究子分析
Shobana Anpalakhan1, Prerana Huddar2, Roya Behrouzi2
1Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.
在接受一线化疗免疫治疗的高级非小细胞肺癌患者中,与免疫治疗相关的不良反应 (irAEs) 与改善的整体存活率 (OS) 和无进展存活率 (PFS) 相关. 较低的中性粒细胞与淋巴细胞比率 (NLR) 和系统性免疫炎症指数 (SII) 与irAE发生相关.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺癌研究研究 肺癌研究
背景情况:
- 斯宾纳克研究调查了第一线化疗免疫治疗中高级非小细胞肺癌 (NSCLC) 患者的现实生存结果.
- 这次子分析的重点是免疫治疗相关的不良反应 (irAEs),它们对生存的影响以及相关的临床因素.
研究的目的:
- 评估irAEs对NSCLC患者的整体生存期 (OS) 和无进展生存期 (PFS) 的发生率和影响.
- 在接受一线化疗免疫治疗的患者中确定与irAE发生相关的临床因素.
主要方法:
- 对308名接受布罗利祖马布加化疗治疗的NSCLC患者进行了回顾性多中心观察队列研究.
- 收集了关于患者特征,生存率,irAEs (频率和严重程度) 以及免疫炎症标志物 (NLR,SII) 的数据.
主要成果:
- 43%的患者经历了任何级别的IRE;16%的患者有 3-4 级的IRE.
- 与没有任何等级的irAEs患者相比,患有任何等级的irAEs患者的中位寿命显著更长 (17.5 vs. 10.1个月) 和PFS (10.1 vs. 6.1个月) 相比.
- 较高的irAE率与较低的NLR (<4),较低的SII (<1,440),更好的治疗反应和特定的NHS-肺预后类相关.
结论:
- 接受化疗免疫治疗的NSCLC患者的irAEs与改善的生存结果有关.
- 较低的NLR和SII值可能预测有更高的经历irrAEs的可能性,特别是1-2级irrAEs.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
